Objective: Antipsychotic monotherapy is considered as the reference standard in the pharmacological treatment of schizophrenia. Nonetheless, there is a large rate of studies showing polypharmacy with antipsychotics as more frequent than would be expected attending experts_ recommendations. The objective of this study is to describe polypharmacy with antipsychotic regimen in patients with schizophrenia discharged with amisulpride from the short-term hospitalization unit.
T he use of antipsychotic agents in monotherapy is considered the standard treatment for schizophrenia and other psychotic disorders. 1Y5 Unfortunately, despite advances in the treatment of schizophrenia, 30% of the patients do not respond or only respond partially to pharmacological treatment. 6 According to the different clinical guides, clozapine should be the treatment of choice for patients partially responding to other antipsychotic drugs. 7 The data available from follow-up studies, however,
show that 47% to 63% of the patients treated with clozapine do not present an appropriate response. 8 Some data also suggest that clinicians often use polypharmacy with antipsychotic agents (PA) before using clozapine. 9 This situation is probably due to the need to monitor the patient when clozapine is prescribed due to its undesirable effects. In a clinical context of a psychiatric emergency service, and despite clinical guide recommendations, strategies combining it with other antipsychotic agents seem to be growing in importance.
There are numerous studies on prescription habits published in different media showing that PA is much more common than would be expected in view of the experts_ recommendations (Table 1) . Four randomized, double-blind clinical trials have been published to date analyzing the association of antipsychotic drugs in the treatment of schizophrenia in patients resistant to treatment with clozapine in monotherapy ( Table 2) . One of the studies found a positive effect in the clozapine-sulpiride combination when compared with clozapine-placebo. 29 The other 3 clinical trials 30Y32 analyze the efficacy of the clozapinerisperidone combination in resistant patients with schizophrenia; only the study by Josiassen et al 31 found differences supporting the use of the clozapine-risperidone combination.
In recent years, the use of amisulpride as an adjuvant in the treatment of schizophrenia has awakened the interest of both investigators and clinicians. 33Y41 In a study conducted by our group in 2005 comprising a review of the clinical records of 209 patients with schizophrenia, 55.5% of PA was recorded upon discharge. The patients received an average of 3.06 psychotropic drugs upon discharge and an average of 1.61 antipsychotic agents. We observed that amisulpride was the antipsychotic agent most used as adjuvant treatment. 28 The objective of this study is to describe prescription patterns with amisulpride in patients with schizophrenia or schizoaffective disorder discharged from the short-term hospitalization unit with a PA regimen.
METHODS
This study contemplates a subsample of the patients participating in a larger study reviewing the psychotropic drugs prescribed upon discharge to patients older than 18 years diagnosed with schizophrenia or schizoaffective disorder (International Statistical Classification of Diseases, 10th Revision) admitted to a psychiatric hospital_s short-term hospitalization unit during 2005 and discharged to the community or other intermediate resources.
This article describes the prescription of psychotropic drugs upon discharge in 52 patients who were discharged with amisulpride. Variables were included to describe the following treatments: antipsychotic (drug and dose), benzodiazepine, and anticholinergic agents. Sociodemographic and clinical variables were also collected: age, sex, diagnosis (International Statistical Classification of Diseases, 10th Revision), number of total admissions, number of admissions in the study period from January to December 2005, and length of hospitalization.
The review method consisted of systematically examining the discharge reports of all the patients to obtain uniform information about the entire sample, assuming that discharge can be considered an indicator of clinical stability, 17 at least of the psychotic symptoms leading to hospitalization. Psychotropic 
RESULTS

Demographic Data and Subgroups
Of the 52 patients discharged on amisulpride, 12 (23.1%) were on monotherapy regimen and the remaining 40 (76.9%) on PAregimen. Of these patients, 29 (72.5%) were discharged on 2 antipsychotic agents and 11 (17.5%) on 3. Table 3 shows the distribution of the sample according to its sex and age.
Diagnosis Upon Discharge
Regarding diagnosis, 75% of the patients presented schizophrenia of the paranoid subtype; in the group of patients treated with 2 antipsychotics, the paranoid subtype was the most common (79.3%). Overall, 8 of 52 patients (15.4%) were also diagnosed with substance abuse or dependence, of which 1 (8.3%) belonged to the monotherapy group, 4 (13.7%) to the group treated with 2 antipsychotics, and 3 (27.3%) to the group treated with 3 antipsychotics. The frequency of diagnosis of schizoaffective disorder was 18% in the patients treated with 3 antipsychotics and 10.3% in the patients treated with 2 antipsychotics (Table 3) . 
Admission to the Short-Term Hospitalization Unit
The complete review of each clinical record revealed that patients discharged with monotherapy were admitted an average of 7 occasions, those discharged with 2 antipsychotics were admitted on 6 occasions, and those treated with 3 antipsychotics were admitted on 8 occasions. Clinical data recorded during 2005 only showed that the average number of admissions during the year was twice or less for each of the 3 subgroups of patients. The mean duration of hospitalization was 30.8 days in the patients discharged on monotherapy, 21.6 days in those discharged on 2 antipsychotics, and 32.4 days in those treated with 3 antipsychotics (Table 3) .
Treatment Upon Discharge
The mean dose of amisulpride used was 825 T 241.68 mg in the group treated with amisulpride in monotherapy, 803.4 T 330 mg in the group treated with 2 antipsychotics, and 1000 T 296.6 mg in the group treated with 3 antipsychotics (Table 4 ). In the group treated with 2 antipsychotics, the most common combination was with a classic antipsychotic in depot formulation. Amisulpride was combined with a great variety of atypical antipsychotic agents. Eleven patients (17.5%) were prescribed to another 2 antipsychotics in addition to amisulpride, being the most common combination with amisulpride, a second-generation antipsychotic, and classic or depot antipsychotic.
DISCUSSION
Lack of response to treatment in patients with schizophrenia is one of the principal problems facing clinicians in psychiatric practice. Although there is a broad therapeutic arsenal available, clinicians often choose PA as a therapeutic strategy to control the symptoms ( Table 1) . The high frequency of use of PA, particularly in patients admitted to specialist units, would seem to show that PA is not just a therapeutic strategy for treating patients resistant to clozapine. According to Tapp et al, 9 PA is often chosen in clinical practice even before instating treatment with clozapine due to the management difficulties involved with this antipsychotic agent. The principal argument against the use of PA is the poor scientific evidence to support the practice (Table 2) , 29Y31 as well as the possible pharmacological interactions and undesirable side effects that may appear and should be taken into consideration.
Amisulpride is a highly selective D 2 /D 3 dopaminergic receptor antagonist, with activity primarily in the limbic system. 42 It presents a low rate of extrapyramidal side effects and a low sedation profile, leading to good subjective tolerance and favoring compliance with treatment. 43 These pharmacological characteristics make it an interesting adjuvant agent. In patients with a partial response to clozapine, adjuvant treatment with amisulpride can provide selective blockage of the D 2 receptors in the limbic system, which would supplement the low activity of clozapine on this subtype of receptors. 44 In fact, 9.7 mo 543 (223) Cl (7) 6 (85.7)
Cook et al 39 also studied patients diagnosed with schizophrenia and schizoaffective disorder in whom a significant improvement was observed in 11 of the 14 cases studied; no serious side effects were recorded in this study.
In our opinion, there are 2 groups of patients with schizophrenia who could benefit from the use of PA composed by amisulpride and another antipsychotic as the therapeutic strategy of choice. The first group, as we observed in reviewed literature, comprises patients presenting a partial response to clozapine. The second, according to Stahl, 45 consists of patients who generally require hospitalization, with acute psychotic processes and associated behavioral disorders, particularly aggressiveness where the clinician adds an antipsychotic with a high affinity for D 2 receptor blockade. In both cases, it is advisable to resume monotherapy once the situation is stable. 1 The frequency of PA found in our sample is greater than could be attributed to strategies intending to treat only refractory schizophrenic patients. In our study, this second group of patients with acute psychotic symptoms and severe behavioral disorders would be represented in the group receiving 2 antipsychotic agents (amisulpride + another antipsychotic), 55.7% of the sample. These patients are fundamentally men (75.9%), younger (mean age of 37.1 T 8.7 years) than the patients treated with monotherapy (mean age of 41.6 T 11.3 years), and with a higher frequency of the paranoid subtype (79.3%) than the monotherapy group (75%). The length of hospitalization in the group treated with 2 antipsychotics is shorter (21.6 T 13.5 days) than in the group treated with monotherapy with amisulpride (30.8 T 42.7 days).
If we consider the total of 209 studied patients, we found 2 other data that support this hypothesis. On the one hand, the low use of clozapine in our sample (only 7 patients were treated with clozapine and none in monotherapy), which indicates that PA is not considered solely as a strategy to treat refractory schizophrenic. On the other hand, amisulpride was the antipsychotic most frequently used as an adjuvant in all the groups. It was administered in 43.2% of typical depot-atypical antipsychotics combinations, in 34.6% of typical-atypical antipsychotics combinations, and in 69.2% of atypical-atypical antipsychotics combinations. These data suggest the selection of tools of high affinity and selectivity for D 2 receptor antagonist.
The principal limitation of our study is its design and the lack of scales measuring the psychopathology and side effects, which would provide more solid data related to observed response and safety. However, because the information is obtained from patients_ discharge reports, we can assume that patients are stable in their positive symptoms, and that their tolerance to treatment is suitable when they are discharged. 17 Although the naturalistic design of this study does not allow to make specific recommendations, the National Association of State Mental Health Program Directors 46 recognizes in their final recommendations that the double-blind randomized clinical trials present unsolvable methodological limitations to evaluate the effectiveness of the psychotropic drug combinations and suggest that the naturalistic studies would have to be used and accepted like mechanism to identify the optimal combinations of antipsychotics.
The results of our study and the review of the literature show that the use of amisulpride as an adjuvant can be a suitable therapeutic strategy for patients with schizophrenia or schizoaffective disorder not only resistant to treatment but also for the rapid control of symptoms in schizophrenic patients with acute episodes. New prospective, randomized, doubleblind studies are required, however, to test the efficacy of amisulpride as an adjuvant in these patients.
